Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Michelson

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Neurology|December 1, 2012
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexantW Joseph Herring, Ellen Snyder, Kerry Budd, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 17, 2020
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trialW Joseph Herring, Paulette Ceesay, Ellen Snyder, et al.
Sleep Medicine|August 8, 2013
Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover studyW Joseph Herring, Kenneth Liu, Jill Hutzelmann, et al.
The American Journal of Psychiatry|February 19, 2008
Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential responseJeffrey H Newcorn, Christopher J Kratochvil, Albert J Allen, et al.
Drug Safety|July 17, 2003
Cardiovascular effects of atomoxetine in children, adolescents, and adultsJoachim F Wernicke, Douglas Faries, Donald Girod, et al.
Pediatric Research|March 19, 2005
Use of opioids in asphyxiated term neonates: effects on neuroimaging and clinical outcomeDanilyn M Angeles, Nathaniel Wycliffe, David Michelson, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|June 24, 2004
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled studyDavid Michelson, Jan K Buitelaar, Marina Danckaerts, et al.
The Journal of Clinical Psychiatry|August 21, 2012
Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorderW Joseph Herring, Timothy E Wilens, Lenard A Adler, et al.
Biological Psychiatry|August 9, 2006
A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 yearJan K Buitelaar, David Michelson, Marina Danckaerts, et al.
Journal of Attention Disorders|November 21, 2007
The reliability and validity of self- and investigator ratings of ADHD in adultsLenard A Adler, Stephen V Faraone, Thomas J Spencer, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Neurology|December 1, 2012
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexantW Joseph Herring, Ellen Snyder, Kerry Budd, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 17, 2020
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trialW Joseph Herring, Paulette Ceesay, Ellen Snyder, et al.
Sleep Medicine|August 8, 2013
Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover studyW Joseph Herring, Kenneth Liu, Jill Hutzelmann, et al.
The American Journal of Psychiatry|February 19, 2008
Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential responseJeffrey H Newcorn, Christopher J Kratochvil, Albert J Allen, et al.
Drug Safety|July 17, 2003
Cardiovascular effects of atomoxetine in children, adolescents, and adultsJoachim F Wernicke, Douglas Faries, Donald Girod, et al.
Pediatric Research|March 19, 2005
Use of opioids in asphyxiated term neonates: effects on neuroimaging and clinical outcomeDanilyn M Angeles, Nathaniel Wycliffe, David Michelson, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|June 24, 2004
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled studyDavid Michelson, Jan K Buitelaar, Marina Danckaerts, et al.
The Journal of Clinical Psychiatry|August 21, 2012
Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorderW Joseph Herring, Timothy E Wilens, Lenard A Adler, et al.
Biological Psychiatry|August 9, 2006
A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 yearJan K Buitelaar, David Michelson, Marina Danckaerts, et al.
Journal of Attention Disorders|November 21, 2007
The reliability and validity of self- and investigator ratings of ADHD in adultsLenard A Adler, Stephen V Faraone, Thomas J Spencer, et al.
Pageof 9